

1 **A marker-free co-selection strategy for high efficiency human genome engineering**

2

3 Daniel Agudelo^{1*}, Lusiné Bozoyan^{1,2*}, Alexis Durringer^{1*}, Caroline C. Huard¹, Sophie
4 Carter¹, Jeremy Loehr¹, Dafni Synodinou¹, Mathieu Drouin², Jayme Salsman³, Graham
5 Dellaire³, Josée Laganière², and Yannick Doyon^{1,4}.

6

7 ¹ Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine,
8 Laval University, Quebec City, QC G1V 4G2, Canada.

9 ² Research and Development, Héma-Québec, Quebec City, QC G1V 5C3, Canada.

10 ³ Department of Pathology, Dalhousie University, Halifax, Nova Scotia, B3H 4R2,
11 Canada

12

13 *These authors contributed equally to this work

14

15 ⁴Address correspondence to:

16

17 Yannick Doyon, Ph.D.
18 Centre de recherche du CHU de Québec – Université Laval
19 2705, boulevard Laurier, T-3-67
20 Québec, QC G1V 4G2
21 CANADA
22 Tel: 418-525-4444 ext. 46264
23 e-mail: Yannick.Doyon@crchudequebec.ulaval.ca

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38 **ABSTRACT**

39 **Targeted genome editing using engineered nucleases facilitates the creation of *bona***
40 ***fide* cellular models for biological research and may be applied to human cell-based**
41 **therapies. Broadly applicable and versatile methods for increasing the levels of gene**
42 **editing in cell populations remain highly desirable due to the variable efficiency**
43 **between distinct genomic loci and cell types. Harnessing the multiplexing**
44 **capabilities of CRISPR-Cas9 and Cpf1 systems, we designed a simple and robust co-**
45 **selection strategy for enriching cells harboring either nuclease-driven non-**
46 **homologous end joining (NHEJ) or homology-directed repair (HDR) events.**
47 **Selection for dominant alleles of the endogenous sodium-potassium pump (Na^+, K^+ -**
48 **ATPase) that render cells resistant to ouabain is used to enrich for custom**
49 **modifications at another unlinked locus of interest, effectively increasing the**
50 **recovery of engineered cells. The process was readily adaptable to transformed and**
51 **primary cells, including hematopoietic stem and progenitor cells (HSPCs). The use**
52 **of universal CRISPR reagents and a commercially available small molecule**
53 **inhibitor streamlines the incorporation of marker-free genetic changes in human**
54 **cells.**

55

56

57

58

59

60

61 INTRODUCTION

62 Designer nucleases such as zinc-finger nucleases (ZFNs), TAL effector nucleases
63 (TALENs), and CRISPR systems greatly simplify the generation of cell lines with
64 tailored modifications enabling the study of endogenous genetic elements in human cells
65 in an unparalleled manner¹⁻³. In particular, CRISPR-based technologies enable
66 researchers to introduce double-strand breaks (DSBs) to virtually any DNA sequences
67 using sequence-specific guide RNAs that target Cas9 and Cpf1 nucleases to cleave the
68 matching sequence. The ensuing DSBs activate two competing repair pathways, namely
69 NHEJ and HDR to facilitate the precise modification of the targeted endogenous locus.
70 NHEJ repairs the lesion by directly rejoining the two DSB ends without the need for a
71 repair template resulting in either precise religation or formation of small insertion or
72 deletion mutations (indels) at the break site. In contrast, definite sequence changes can be
73 introduced when the HDR machinery uses an exogenous DNA template with sequence
74 homology to the DSB site to repair the lesion (reviewed in⁴).

75

76 While reprogramming the CRISPR apparatus requires trivial molecular biology skills,
77 the cellular activity of different guide RNAs can vary considerably, even when targeting
78 adjacent sequences. Computational guide RNA selection is complex and further
79 optimization is required before accurate prediction of the optimal sequences can be
80 achieved, a limitation that is exacerbated when the target site is restricted to a narrow
81 genomic region^{5, 6}. Furthermore, the efficiency of delivery and expression of CRISPR
82 components and donor templates can be highly variable between cells of different origin,
83 greatly affecting overall efficacy. Cell type, cell state, and cell cycle stage also play a

84 major role in determining the efficiency of genome editing as human cells dictate repair
85 outcome and have a propensity to favor NHEJ over HDR. Thus, identifying active guide
86 RNAs, screening and isolating clones with the desired genetic modification can be time
87 consuming and costly. In addition, achieving high levels of gene editing is required for
88 accurate phenotypic analysis when studying bulk populations of cells.

89

90 At its most basic level, higher genome editing frequencies are associated with
91 higher nuclease levels and activity. Consequently, several approaches have been
92 implemented to capture and isolate these subpopulations of cells in order to expedite the
93 generation of isogenic knockout and knock-in clones. First, co-transfection of fluorescent
94 proteins combined with fluorescence-activated cell sorting (FACS) can be used to isolate
95 nuclease-expressing cells⁷. Second, direct coupling of expression of fluorescent proteins
96 and nucleases via 2A peptide sequences allows for efficient isolation of cell populations
97 with increasingly higher nuclease expression levels, which translates into increasingly
98 higher genome editing rates⁸. Fluorescence-based surrogate target gene reporters have
99 also been successfully used to enrich for cells with high nuclease activity^{9,10}. A limitation
100 of these methods is that single-cell FACS enrichment is not suitable for more sensitive
101 cell lines. In addition, multi-DSBs arising from cleavage of the episomal reporter
102 plasmids are likely to induce a gene-independent antiproliferative response as recently
103 described for CRISPR-Cas9-induced DNA breaks¹¹. Finally, enhancing HDR-mediated
104 processes by altering cell cycle parameters, the timing of nuclease expression, chemical
105 inhibition of NHEJ and use of HDR agonists show promising results but their general

106 applicability and absence of negative effects on specificity and genome integrity need to
107 be thoroughly evaluated¹²⁻¹⁷.

108

109 Conceptually distinct and elegant genetic approaches based on the creation of
110 “classical” gain-of-function alleles have been developed in the worm *Caenorhabditis*
111 *elegans*. Termed “co-conversion”/ “co-CRISPR”, these methods increase markedly the
112 odds of detecting a phenotypically silent targeted mutation through the simultaneous “co-
113 conversion” of a mutation in an unrelated target that causes a visible phenotype^{18, 19}. It
114 was found that simultaneous introduction of sgRNAs to two different endogenous loci
115 results in double editing events that are not statistically independent. For both NHEJ and
116 HDR-driven modifications, the occurrence of a cleavage and repair event in one locus
117 enhances the probability of finding a heritable mutagenetic event in a second locus in the
118 same animal. A related approach has been described to isolate human cells harboring
119 NHEJ-driven mutations by co-targeting the X-linked hypoxanthine phosphoribosyl-
120 transferase (*HPRT1*) gene²⁰. Although relatively efficient, this technique uses a
121 mutagenic chemotherapy drug, does not select for HDR-based events, and may affect the
122 salvage pathway of purines from degraded DNA. Hereditary HPRT1 deficiency is also
123 the cause of Lesch-Nyhan syndrome. More recently, it was found that, in mouse
124 embryonic stem cells, the CRISPR-Cas9-mediated insertion of a drug-selectable marker
125 at one control site frequently coincided with an insertion at an unlinked, and
126 independently targeted site²¹. Still, the insertion of a heterologous selection cassette into
127 the genome of the edited cells may limit applications of this technique. Hence, further
128 refinement of these approaches is needed.

129 Here we devised a robust marker-free co-selection strategy for CRISPR-driven
130 NHEJ- and HDR-based editing events in human cells by generating dominant cellular
131 resistance to ouabain, a highly potent plant-derived inhibitor of the Na⁺,K⁺-ATPase^{22, 23}.
132 The Na⁺,K⁺-ATPase (also known as the sodium-potassium pump), encoded by the
133 *ATP1A1* gene, is the ion pump responsible for maintenance of the electrochemical
134 gradients of Na⁺ and K⁺ across the plasma membrane of animal cells. It is an essential and
135 ubiquitously expressed enzyme functioning as a heteromeric complex consisting of a
136 large α -subunit (ATP1A1), which is responsible for ATP hydrolysis and ion transport and
137 a β -subunit, acting as a chaperone^{22, 23}. Cardiotonic steroids (CTSs), such as ouabain
138 (PubChem CID: 439501), constitute a broad class of specific Na⁺,K⁺-ATPase inhibitors
139 prescribed for congestive heart failure for more than 2 centuries²³. Many mutagenesis and
140 modeling studies have been carried out on the structure-activity relationships of ouabain
141 clearly defining its mechanism of action and leading to the identification of inhibitor-
142 resistant enzymes²²⁻²⁵. Using CRISPR-Cas9 and CRISPR-Cpf1, we generated gain-of-
143 function alleles in *ATP1A1* via either the NHEJ or the HDR DNA repair pathways that
144 were used to co-select, through resistance to ouabain, for mechanistically related editing
145 events at a second locus of interest. This strategy was portable to many guide RNAs,
146 independent of cell type, and is a general solution for facilitating the isolation of genome-
147 edited human cells.

148

149

150

151

152 **RESULTS**

153 **Editing the endogenous *ATP1A1* locus via either NHEJ or HDR provokes robust**
154 **cellular resistance to ouabain**

155 Crystal structures of the sodium-potassium pump with bound ouabain and related
156 CTSs have revealed that the inhibitors are wedged very deeply between transmembrane
157 helices in addition to contacting the extracellular surface^{22, 23}. Accordingly, random
158 mutagenesis and overexpression studies have pinpointed residues affecting ouabain
159 sensitivity that are localized throughout the protein with clusters of residues conferring
160 the greatest resistance occurring at the H1-H2 transmembrane and extracellular regions²⁴.
161 Most prominently, replacement of the border residues (Q118 and N129) of the first
162 extracellular loop with charged amino acids generates highly resistant enzymes when
163 overexpressed in cells²⁵ (**Fig. 1a**). However, it is unknown if deletions in this regions can
164 disrupt ouabain binding while preserving the functionality of ATP1A1. Furthermore, it
165 remains to be demonstrated if modification of the endogenous locus, as opposed to
166 overexpression of the mutant enzyme, can result in cellular resistance to ouabain.
167 Therefore, we tested whether targeting this region using the CRISPR-Cas9 system could
168 induce such a phenotype.

169

170 We identified two highly active sgRNAs targeting SpCas9 to the exon encoding the
171 first extracellular loop (hereafter named G2 and G4) and one sgRNA targeting the
172 adjacent intron (hereafter named G3) (**Fig. 1a,b**). Starting three days post transfection the
173 cells were treated with ouabain and monitored for survival and growth. Active nucleases
174 targeting the coding sequence (G2 and G4) induced cellular resistance while cells cleaved

175 in the intron with G3 all died within 48 hours (**Fig. 1a,b**). In agreement with previous
176 reports, we have not observed any spontaneous resistance to ouabain treatment^{24, 25}. As
177 *ATP1A1* is essential for cell survival, these observations suggest that in frame insertions
178 and deletions were created in the first extracellular loop preventing ouabain binding
179 without crippling enzymatic activity. To assess the spectrum and frequency of targeted
180 mutations generated in these pools of cells we used the TIDE (Tracking of Indels by
181 DEcomposition) method²⁶. This analysis revealed that in-frame deletions are selected for
182 over time and upon ouabain treatment and that G2 generates a much more diversified set
183 of mutations than G4, which correlates with a higher fraction of in frame deletions and
184 more robust growth (**Supplementary Fig. 1**). It also shows that the surveyor nuclease
185 assay used to determine the frequency of small insertions and deletions (indels)
186 characteristic of imprecise DSB repair by NHEJ (hereafter, the acronym NHEJ will be
187 used to describe mutagenic repair since the precise religation of the DSBs cannot be
188 detected using this assay) saturates when samples with high levels of modification are
189 tested (**Fig. 1b**). Cloning and sequencing *ATP1A1* alleles from ouabain-resistant cells
190 identified in frame deletion products resulting in disruption of the first extracellular loop
191 of the pump (**Fig. 1c**).

192

193 Next, we aimed to test whether it was possible to create gain-of-function alleles by
194 HDR. Reaching a high threshold of HDR in human cells is a major challenge in the
195 genome-editing field since, at the population level, cells favor DSB repair via NHEJ over
196 HDR. Therefore, cleaving within the coding sequence of *ATP1A1* would disfavor the
197 recovery of cells edited through HDR at the expense of cells mutated via NHEJ since

198 ouabain would select for both type of repair events. We took advantage of the highly
199 active sgRNA G3 that targets SpCas9 to the intron to achieve selection exclusively via
200 HDR-driven events (**Fig. 1b,d**). Two single-stranded oligos (ssODNs) were designed to
201 create *ATPIA1* alleles conferring ouabain resistance by replacing both border residues of
202 the first extracellular loop with charged amino acids²⁵. The ssODN donors create the
203 double replacements Q118R, N129D (RD) and Q118D, N129R (DR), destroy the
204 protospacer-adjacent motif (PAM) and include additional silent mutations to create
205 restriction sites to facilitate genotyping (**Fig. 1d**). Cas9-expressing cells were co-
206 transfected with sgRNA G3 along with ssODNs and growth was monitored following
207 addition of ouabain. Cells survived and grew robustly only in the presence of the nuclease
208 and either donors. Restriction fragment length polymorphisms (RFLP) assays confirmed
209 the introduction of the desired sequence changes and their enrichment upon ouabain
210 treatment (**Fig. 1e** and **Supplementary Fig. 2**). In addition, increasing the dose of
211 ouabain selected for the double mutants within the population (**Supplementary Fig. 2**).
212 This was not totally unexpected since single mutations at either position confer an
213 intermediate level of resistance²⁵. We speculate that it may be possible to select cells
214 having experienced longer gene conversion tracks by increasing the dose of ouabain
215 during selection. Titration of ouabain in the culture medium indicates that cells modified
216 through HDR are resistant to concentration of the drug of at least 1mM, which is more
217 than 100 fold higher than for NHEJ-induced mutations and more than 2000 fold higher
218 than what is needed to kill the cells (0.5µM). These values correspond to the level of
219 resistance observed in cells overexpressing the mutant enzymes and highlight the wide
220 range of doses that can be used for selection²⁵. Thus, optimization of the drug-based

221 selection process for various cell lines is straightforward as it is not necessary to precisely
222 titrate the amount of ouabain required for selection.

223

224 These results could be reproduced using the type V CRISPR system from
225 *Acidaminococcus* sp. Cpf1 (AsCpf1), a single-RNA-guided (crRNA) enzyme that
226 recognizes a TTTN PAM and produces cohesive double-stranded breaks (DSBs)²⁷
227 **(Supplementary Fig. 2).**

228

229 In addition, this positive selection was also observed in U2OS, HEK293 and the
230 diploid hTERT-RPE1 cells **(Supplementary Fig. 2** and below). We note that, in selected
231 cells with more than two copies of *ATPIAI*, the fraction of in-frame indels or HDR-
232 alleles can be lower than 50%. For example, in a triploid cell line, the minimal expected
233 signal for these dominant gain-of-function mutations is 33%. Thus, we identified highly
234 active CRISPR-Cas9 and CRISPR-Cpf1 RNA-guided nucleases capable of producing
235 gain-of-function alleles at the *ATPIAI* locus via either NHEJ or HDR.

236

237 **Co-selection strategy for enriching cells harboring CRISPR-driven gene disruption**
238 **events**

239 To test whether selection for the above mentioned gain-of-function alleles in
240 *ATPIAI* can result in co-enrichment of NHEJ-driven mutations at a second locus, we
241 built an all-in-one vector containing tandem U6-driven sgRNA expression cassettes along
242 with CBh-driven high specificity eSpCas9(1.1)²⁸ **(Fig. 2a,b)**. Cells were transfected with
243 a vector for targeting both *EMXI* and *ATPIAI* and either selected with ouabain or left

244 untreated before genomic DNA was harvested. The frequencies and spectrum of indels in
245 these cell populations was determined by TIDE revealing a marked increase in gene
246 disruption reaching as high as 83% upon selection (**Fig. 2c** and **Supplementary Fig. 3**).
247 In these experiments, transfection of low and high doses of vector was used to simulate
248 the impact of co-selection at a broad range of gene editing frequencies. Similar results
249 were obtained when co-targeting the *AAVSI* and *ATPIAI* loci (**Fig. 2d** and
250 **Supplementary Fig. 3**). In this experiment, the 500ng vector dose transfection was very
251 efficient and starting gene disruption levels were high at both *ATPIAI* and *AAVSI* and no
252 further increase was observed following ouabain treatment (**Fig. 2d**). Surveyor assays
253 performed on all samples corroborated these results (**Supplementary Fig. 4**). Despite
254 reaching almost saturating on-target disruption rates, we could not detect activity at
255 known off-target sites for both *EMXI* and *AAVSI* in these stably modified cell
256 populations^{28, 29} (**Supplementary Fig. 4**). These data indicate that the co-selection
257 process does not negatively impact the enhanced specificity of the eSpCas9(1.1)
258 variant²⁸.

259

260 Next, we took advantage of the multiplexing capacity of the CRISPR–Cpf1 system
261 to perform co-selections using all-in-one AsCpf1 expression vectors containing crRNA
262 arrays³⁰. We observed improvements in gene disruption efficiency for all four previously
263 published guides, whether expressed in pairs with the *ATPIAI*-targeting guide or as a full
264 array co-expressing five guides simultaneously (**Fig. 2e-h** and **Supplementary Figs. 5**
265 **and 6**). These results were reproduced in the HEK293 cell line (**Supplementary Figs. 5**
266 **and 6**). As previously observed for SpCas9, the pattern of DNA repair following

267 eSpCas9(1.1) and AsCpf1 cutting at each site is nonrandom, consistent across cell lines
268 and independent of absolute efficacy³¹. AsCpf1 has been shown to be highly specific for
269 its target based on genome-wide specificity assays in human cells so only one known off-
270 target site could be tested amongst the four guides used in the present study^{32,33}. While
271 we observed off-target cleavage for the *DNMT1*-targeting guide in transiently transfected
272 K562 cells we could not detect mutagenesis at this site in ouabain selected cells, even
273 though the on-target activity was superior (**Supplementary Fig. 7**). In contrast, in
274 HEK293, off-target activity was low but apparent (**Supplementary Fig. 7**). Thus, it
275 appears that the co-selection process does not result in overt off-target activity.
276 Collectively, these data show that CRISPR-driven gain-of-function mutations at the
277 endogenous *ATPIAI* gene can be used efficiently for co-selection via NHEJ.

278

279 **Robust co-selection for cells harboring CRISPR-driven HDR events**

280 We then tested if selection for cells having experienced a CRISPR-driven HDR
281 event at *ATPIAI* could provide a substantial enrichment for correctly targeted cells at a
282 second locus. We targeted two endogenous genes to generate N- and C-terminal fusions
283 with fluorescent proteins in order to facilitate the quantification of HDR events through
284 FACS-based analysis. To label chromatin, the *HIST1H2BK* locus was targeted to create a
285 C-terminal fusion of H2B with monomeric Azami-Green (mAG1) (**Fig. 3a**). For both
286 wild-type (WT) and eSpCas9(1.1) the fraction of cells expressing the fusion protein
287 increased from below 1% to ~13-15% after ouabain treatment (**Fig. 3b**). The absence of
288 promoter elements in the homology arms of the donor vector along with the clear
289 chromatin-linked fluorescent signal suggests that the process enriched for correctly

290 targeted cells (**Fig. 3c**). Next, we inserted the coding sequence for the green fluorescent
291 protein Clover or the red fluorescent protein mRuby2 after the second codon of the
292 *LMNA* gene, which encodes the lamin A and lamin C isoforms¹⁷ (**Fig. 3d**). For both
293 Clover and mRuby2 donors we detected a marked increase in signal ranging from ~5-6%
294 to ~40-50% upon ouabain selection and the cells displayed the distinct localization
295 pattern of fluorescence enriched at the nuclear periphery (**Fig. 3e** and **Supplementary**
296 **Fig. 8**). Co-transfection of the Clover and mRuby2 donors along with the *LMNA* and
297 *ATPIAI*-targeting nucleases permitted to visualize the enrichment of double-positive
298 cells, demonstrating that bi-allelic targeting can be achieved upon ouabain selection (**Fig.**
299 **3e**). The level of improvement in gene targeting at the co-selected *LMNA* locus paralleled
300 HDR rates at *ATPIAI* as determined by RFLP assays (**Fig. 3f**). To determine whether the
301 enrichment at the co-selected *LMNA* locus occurs solely for alleles that repaired the DSB
302 via HDR, or whether NHEJ-produced alleles are also enriched for, we performed out-out
303 PCR analysis on ouabain selected samples followed by TOPO cloning and sequencing
304 (**Supplementary Fig. 9**). Sequencing of 44 non-targeted alleles revealed 7 WT sequences
305 and 37 alleles with indels at the predicted cleavage site (**Supplementary Fig. 9**). Thus,
306 NHEJ-produced alleles are also enriched for but a fraction of the cells are likely to have
307 both a targeted and a WT allele. Sequencing of the targeted alleles also indicates that the
308 integration occurred through homologous recombination. Similarly, sequencing of
309 *ATPIAI* alleles revealed 10 WT, 35 NHEJ, and 39 HDR-related events out of 84 reads
310 (**Supplementary Fig. 9**). None of the NHEJ-based deletions extended to the exon.
311 Among HDR events, directional co-conversion of SNPs from the DSB was evident (see
312 **Fig. 1d**). All 39 clones had incorporated the *Cla*I site (mutated PAM), 30 had

313 incorporated both the ClaI and the BmgBI sites, and 17 had integrated the 3 RFLP sites.
314 As observed for H2BK, co-selection was efficient for both WT SpCas9 and eSpCas9(1.1)
315 and co-selection using AsCpf1 was also achieved in this system (**Supplementary Fig. 8**).
316 Stimulation of targeted integration of transgene cassettes was also successful at two
317 distinct loci, namely *AAVSI* and *HPRT1* (**Supplementary Fig. 8**). Taken together, these
318 data demonstrate that co-selection for ouabain resistant cells markedly improved the
319 outcome of HDR-driven gene editing experiments, irrespective of the target locus.

320

321 **Enabling affinity purification of endogenous protein complexes from co-selected** 322 **polyclonal cell populations**

323 Having demonstrated that co-selection could generate highly modified cell
324 populations we tested whether functional assays could be performed directly in these
325 pools, thus bypassing single-cell cloning steps. We used tools that we previously
326 developed to build an interface between genome editing and proteomics in order to
327 isolate native protein complexes produced from their natural genomic contexts, an
328 approach that led to the identification of novel interactions in chromatin modifying and
329 DNA repair complexes³⁴. Using co-selection, we tagged the enhancer of polycomb
330 homolog 1 (EPC1) and the E1A binding protein p400 (EP400), two essential subunits of
331 the NuA4/TIP60 acetyltransferase complex that promote homologous recombination by
332 regulating 53BP1-dependent repair³⁵ (**Fig. 4a,b**). Out-out PCR-based assays and western
333 blotting confirmed the correct integration of the affinity tag at both loci and the
334 enrichment of tagged cells upon ouabain treatment (**Fig. 4c,d**). Nuclear extracts were
335 prepared from the cell pools as well as from WT K562 cells (Mock), and subjected to

336 tandem affinity purification (TAP). EPC1 and EP400 complex subunits separated by
337 SDS–polyacrylamide gel electrophoresis (SDS–PAGE) could be unambiguously
338 identified on silver stained gels and are virtually identical to the patterns obtained from
339 clonal cell lines³⁴ (**Fig. 4e**). Successful tagging via co-selection was also achieved in
340 HEK293 cells (**Supplementary Fig. 10**). These results represent an additional step
341 toward high-throughput genome-scale purification of native endogenous protein
342 complexes in human cells.

343

344 **Efficient enrichment of gene-edited human hematopoietic stem and progenitor cells** 345 **(HSPCs)**

346 To explore the potential for clinical translation of our method we tested the ouabain
347 selection strategy during *ex vivo* expansion of cord blood-derived human hematopoietic
348 stem and progenitor cells (HSPCs). Genome editing in HSPCs by homologous
349 recombination remains challenging but offers the possibility to treat several genetic
350 diseases³⁶. We used previously developed tools to introduce a mutation in the beta-globin
351 (*HBB*) gene causing sickle cell disease (SCD)³⁷⁻³⁹ (**Fig. 5a**). Purified human CD34⁺ cells
352 were electroporated with preformed SpCas9 ribonucleoprotein complexes (RNPs)
353 containing synthetic crRNAs and tracrRNAs targeting *ATP1A1* and *HBB* and ssODNs
354 and expanded *ex vivo* with or without ouabain. Cells were cultivated in presence of
355 UM171 to promote expansion and maintenance of primitive progenitors during
356 selection⁴⁰. RFLP-based assays clearly indicate that cells edited at the *HBB* locus could
357 be efficiently enriched using ouabain, a phenomenon observed in cells isolated from
358 various donors and using different ssODNs (**Fig. 5b,c** and **Supplementary Fig. 11**).

359 These results support the notion that the process could be adapted for use in preclinical
360 studies. Critically, these data demonstrate that the procedure is applicable to diploid
361 primary cells.

362

363 **DISCUSSION**

364 Here we demonstrate that the creation of gain-of-function alleles at the *ATPIAI*
365 locus with CRISPR-Cas9 and Cpf1 can be robustly selected for using a highly potent
366 therapeutic small molecule in order to enrich for custom modifications at another
367 unlinked locus of interest, substantially increasing the recovery of engineered cells. A
368 defining aspect of our system is that the co-selection process can be initiated through
369 NHEJ- or HDR-driven events independently. One only has to switch between two
370 validated sgRNAs targeting juxtaposed regions of *ATPIAI* and include an ssODN in the
371 transfection reaction to co-select for HDR- instead of NHEJ-driven events. Perhaps more
372 importantly, we show that the co-selection strategy markedly enriches for cells modified
373 via homologous recombination, a clear limitation in the field. This was demonstrated at
374 endogenous loci for five different types of HDR-driven genome editing events; (i) RFLP
375 knock-in, (ii) gene trapping, (iii) targeted integration of an autonomous expression
376 cassette, (iv) protein tagging with fluorescent markers, and (v) epitope tagging. As shown
377 in the examples above, the extent of enrichment for HDR-edited cells varied at different
378 sites and according to the type of modification created at the locus of interest. Of
379 particular importance, robust selection is achieved without the use of exogenous DNA
380 markers making it potentially compatible with therapeutic applications. Further work and
381 optimization will reveal if the gene editing and selection process is compatible with a

382 variety of primary cell types. The well-defined mechanism of action of ouabain acting on
383 a non-signaling ion pump independently of proliferation is another distinct advantage of
384 the method. Ouabain treatment kills cells within 48 hours of exposure and targeted cells
385 display no apparent growth delay resulting from the selection process. Accordingly, the
386 point mutations engineered to confer ouabain resistance are naturally occurring in mice,
387 rats, monarch butterflies, leaf beetles, and some toads⁴¹. In addition, these mutant
388 enzymes function normally, as shown by ⁸⁶Rb⁺ uptake and ATP hydrolysis assays²⁵. The
389 turnover of ATP1A1 at the plasma membrane appears to be rapid since ouabain can be
390 added to the culture medium as early as 15 hours post transfection of the CRISPR
391 components, even if they are encoded on plasmids (data not shown). Although not
392 formally tested in this study, the process should be compatible with any engineered
393 nuclease platforms and any cell type since *ATP1A1* is ubiquitously expressed.

394

395 These results corroborate earlier observations that cells proficient at completing one
396 genomic manipulation have an increased probability of completing a second, independent
397 genomic manipulation, provided they are mediated by sufficiently similar mechanisms of
398 DNA repair^{18, 19, 21}. Powerful co-selection schemes such as the one described in this study
399 may offer the opportunity to efficiently correct a mutation “at distance” and avoid
400 complications caused by on-target NHEJ-based mutagenesis of the non-corrected allele.
401 Since about 80% of human exons are < 200 bp in length, it should be possible to cleave
402 within an intron to induce recombination in the juxtaposed exon. Provided the intronic
403 sequence is not repetitive and indels in the intron do not affect gene expression such a
404 strategy should be considered. The concept of creating and selecting for dominant gain-

405 of-function alleles of endogenous genes and its use to enrich for custom modifications at
406 unlinked loci of interest could be broadened to include other protein/drug or cell surface
407 marker/antibody combinations. For example, one could achieve the co-enrichment of
408 edited cells *in vivo* after chemo-selection of transplanted cells modified to express the
409 P140K variant of human O(6)-methylguanine-DNA-methyltransferase (MGMT)⁴².
410 Technically, it is interesting to note that this residue is encoded next to an intron-exon
411 boundary and could be targeted in a similar fashion as *ATPIAI* to favor enrichment of
412 cells edited via HDR (**Supplementary Fig. 11**).

413

414 Remarkably, robust co-selection for NHEJ-based on-target mutagenesis does not
415 yield overt off-target activity when enhanced fidelity variants of SpCas9 are used. In fact,
416 we did not detect mutagenesis at sites where WT SpCas9 is known to cleave. It also
417 appears that the co-enrichment of indels at off-target sites is limited compared to the one
418 observed at on-target loci, as shown for AsCpf1. As the amount of CRISPR components
419 can be titrated to improve the ratio of on-target to off-target mutation rates, an unexpected
420 advantage of the co-selection strategy may be to achieve this balance without reducing
421 the final on-target efficacy. This will hold true if transfecting lower amounts of plasmids
422 results in lower levels of the nuclease on a per-cell basis. Translocations between
423 *ATPIAI* and the locus of interest will occur at some frequency and there is a slight
424 probability that this event will be found in the selected population.

425

426 In conclusion, we established a simple method that can be broadly applied to
427 increase the frequency of genome editing events in human cells. It is easy to implement

428 in any laboratory, as it only requires a universal set of CRISPR reagents and an
429 inexpensive commercially available drug. Furthermore, by design, it was built to be
430 compatible with any nuclease platform and most other strategies developed to facilitate
431 the use of this powerful technology.

432

433 **METHODS**

434 **Cell culture and transfection**

435 K562 were obtained from the ATCC and maintained at 37 °C under 5% CO₂ in RPMI
436 medium supplemented with 10% FBS, penicillin-streptomycin and GlutaMAX. U2OS
437 cells were obtained from the ATCC and maintained at 37 °C under 5% CO₂ in McCoy's
438 5A medium supplemented with 10% FBS, penicillin-streptomycin and GlutaMAX. HEK-
439 293 LTV were purchased from Cell Biolabs and hTERT RPE-1 cells were a kind gift
440 from Amélie Fradet-Turcotte. Both cell lines were maintained at 37 °C under 5% CO₂ in
441 DMEM medium supplemented with 10% FBS, penicillin-streptomycin and GlutaMAX.
442 Cells (2E5 per transfection) were transfected using the Amaxa 4D-Nucleofector (Lonza)
443 per manufacturer's recommendations. Transfection conditions used in co-selections via
444 HDR can be found in Supplementary Table 1. Ouabain octahydrate (Sigma) was
445 dissolved at 50 mg/ml in hot water and stored at -20 °C. Working dilutions were prepared
446 in water and added directly to the culture medium.

447

448 **CRISPR-Cas9 and Cpf1 reagents**

449 The CAG-driven human codon optimized Cas9 nuclease vectors hCas9 was a gift from
450 George Church (Addgene plasmid # 41815)⁴³. The expression cassette was transferred to

451 AAVS1_Puro_PGK1_3xFLAG_Twin_Strep (Addgene plasmid # 68375)³⁴ in order to
452 establish the K562 cell line constitutively expressing Cas9. All sgRNA expression
453 vectors were built in the SP_gRNA_pUC19 backbone (Addgene plasmid # 79892)³⁴, with
454 the exception of gRNA_AAVS1-T2 which was a gift from George Church (Addgene
455 plasmid # 41818)⁴³. Design of sgRNAs was assisted by the GPP Web Portal
456 (<http://portals.broadinstitute.org/gpp/public/>) and the MIT web-based CRISPR design
457 tool (<http://crispr.mit.edu/>). Sequences of the guides are provided in Supplementary Table
458 2. The DNA sequence for the guides were modified at position 1 to encode a ‘G’ due to
459 the transcription initiation requirement of the human U6 promoter when required. The
460 reagents targeting the *LMNA* gene have been described¹⁷. To test the high specificity
461 eSpCas9(1.1) variant, guide sequences were cloned into the eSpCas9(1.1)_No_FLAG
462 vector (Addgene plasmid # 79877). The human codon optimized AsCpf1 ORF from the
463 nuclease vector pY010, a gift from Feng Zhang (Addgene plasmid # 69982)²⁷, was
464 transferred to AAVS1_Puro_PGK1_3xFLAG_Twin_Strep (Addgene plasmid # 68375)³⁴
465 in order to establish the K562 cell line constitutively expressing Cpf1 from a CAG
466 promoter. A crRNA expression vector was built in the pUC19 backbone by linking the
467 AsCpf1 5’DR to a human U6 promoter²⁷. The guide sequences were cloned downstream
468 of the 5’DR. Guide for AsCpf1 were designed using Benchling
469 (<https://benchling.com/academic>) and sequences are provided in Supplementary Table 3.
470 The dual AsCpf1 and U6-driven crRNA array expression vector was built in pY036 (a
471 gift from Feng Zhang) as described³⁰. Desalted ssODNs (Supplementary Table 4) were
472 synthesized as ultramers (IDT) at 4 nmole scale. All plasmid donor sequences contain
473 short homology arms (<1 kb) and have been modified in order to prevent their cleavage

474 by Cas9 as described³⁴. The only exception to this rule was for the targeting of Clover to
475 the *LMNA* locus using AsCpf1. eSpCas9(1.1) and AsCpf1 expression vectors targeting
476 *ATPIAI* have been deposited to Addgene (**Supplementary Fig. 13**).

477

478 **Surveyor nuclease, RFLP knock in assays, out-out PCR assays, and TIDE analysis**

479 Genomic DNA from 2.5E5 cells was extracted with 250 µl of QuickExtract DNA
480 extraction solution (Epicentre) per manufacturer's recommendations. The various loci
481 were amplified by 30 cycles of PCR using the primers described in Supplementary Table
482 5. Assays were performed with the Surveyor mutation detection kit (Transgenomics) as
483 described⁴⁴. Samples were separated on 10% PAGE gels in TBE buffer. For RFLP
484 assays, the PCR products were purified and digested with the corresponding enzyme and
485 resolved by 10% PAGE. Gels were imaged using a ChemiDoc MP (Bio-Rad) system and
486 quantifications were performed using the Image lab software (Bio-Rad). TIDE analysis
487 was performed using a significance cutoff value for decomposition of $p < 0.005$ ²⁶. To
488 analyze targeted integration via out-out PCR, genomic DNA extracted with QuickExtract
489 DNA extraction solution was subjected to 30 cycles of PCR for *LMNA* and 35 cycles for
490 *EPC1* and *EP400* using the primers described in Supplementary Table 6. Amplicons were
491 loaded on 1% agarose gels in TAE buffer.

492

493 **Flow cytometry**

494 The frequency of EGFP, mAG1, Clover, and mRuby2 expressing cells was assessed
495 using a BD LSR II flow cytometer and gated for viable cells using 7-aminoactinomycin
496 D (7-AAD).

497 **TAP**

498 Nuclear extracts and purifications were performed from ~5E8 cells as described³⁴.
499 Approximately 1/30 of the final eluates were loaded without prior precipitation on Bolt
500 4–12% Bis-Tris gels (Life Technologies) and ran for 45 minutes at 200 volts in MOPS
501 buffer. Silver staining was performed using the SilverQuest kit (Life Technologies).

502

503 **Human cord blood (CB) CD34⁺ cell collection and processing**

504 Human umbilical CB samples were collected from donors consenting to procedures
505 approved by the Research Ethic Board of the CHU de Québec - Université Laval.
506 Mononuclear cells were first isolated using Ficoll-Paque Plus density centrifugation (GE
507 Healthcare). Human CD34⁺ hematopoietic stem and progenitor cells (HSPCs) were
508 isolated using CD34 positive selection according to manufacturer's instructions
509 (EasySepTM, StemCell Technologies). Purified CD34⁺ cells were cryopreserved in
510 Cryostor CS10 (StemCell Technologies).

511

512 **HSPC culture, editing and selection**

513 CD34⁺ HSPCs were thawed and cultured in StemSpan ACF (StemCell Technologies)
514 supplemented with 100ng/ml SCF (Feldan), 100ng/ml FLT3-L (Peprotech), 50ng/ml TPO
515 (StemCell Technologies), 10µg/ml LDL (StemCell Technologies) and 35nM UM171
516 (StemCell Technologies) for 16-24h after thawing. Cells were then nucleofected with
517 Cas9 RNP and ssODNs using the Amaxa 4D Nucleofector X unit (Lonza) and the E0-100
518 program according to manufacturer's recommendations. Following nucleofection, cells
519 were incubated at 30°C for 16h and then transferred at 37°C for 2 days. From day 3 post-

520 nucleofection, HSC were transferred to StemSpan ACF (StemCell Technologies)
521 containing 1X StemSpan CD34+ Expansion supplement (StemCell Technologies) and
522 UM171. Ouabain (0.5 μ M) was added to the cells during culture media change at day 5
523 post-nucleofection, replenished every 3-4 days and maintained for 8 days prior to RFLP
524 analysis at D14 post thaw.

525

526 **Synthetic crRNA and tracrRNA complexes and ribonucleoprotein (RNP) formation**
527 **for editing in HSPCs**

528 The Alt-R CRISPR system (Integrated DNA Technologies) was used to produce the
529 *HBB*³⁷⁻³⁹ (CTTGCCCCACAGGGCAGTAA) and *ATP1A1* G4
530 (GTTCTCTTCTGTAGCAGCT) guides. crRNA and tracrRNA were first resuspended
531 to 200 μ M stock solutions in Nuclease-Free IDTE Buffer (Integrated DNA Technologies).
532 For crRNA:tracrRNA complex formation, the two RNA oligos were mixed in equimolar
533 concentrations, heated at 95°C for 5 minutes and transferred to ice immediately.
534 Immediately prior to nucleofection, 50pmol of Cas9 protein (Integrated DNA
535 Technologies) was incubated with 125pmol of crRNA:tracrRNA complexes at RT for 10
536 minutes to form the RNP complexes along with 100pmole of each ssODNs. Note that the
537 *ATP1A1* G3 guide was not active in the Alt-R CRISPR system (Integrated DNA
538 Technologies), thus we used the *ATP1A1* G4 guide to make RNPs. This guide generates
539 low levels of ouabain resistance via NHEJ in HSPCs and robust cell growth is only
540 observed in the presence of ssODN donors (Supplementary Table 4).

541

542

543 **ACKNOWLEDGMENTS**

544 This study was supported by grants from the Natural Sciences and Engineering Research
545 Council of Canada (RGPIN-2014-059680) to Y.D. and the Canadian Institutes of Health
546 Research (CIHR; MOP-84260) to G.D. Salary support was provided by the Fonds de la
547 recherche du Québec-Santé (FRQS) for D.A. and Y.D. and by a bridge grant from the
548 Beatrice Hunter Cancer Research Institute (BHCRI) for J.S. We thank Sabine Elowe,
549 Amélie Fradet-Turcotte, Daniel Durocher, Jacques Côté, and Christian Beauséjour for
550 critical reading of the manuscript as well as the staff at the Hôpital St-Francois d'Assise
551 for their precious help in collecting UCB units.

552

553 **AUTHOR CONTRIBUTIONS**

554 Conceptualization, Y.D.; Methodology, D.A., L.B., A.D., C.C.H., S.C., J.L., and Y.D.;
555 Investigation, D.A., L.B., A.D., C.C.H., S.C., J.L., D.S., M.D., and Y.D.; Resources, J.S.,
556 and G.D.; Writing – Original Draft, Y.D.; Writing – Review and Editing, D.A., L.B.,
557 A.D., S.C., J.L., G.D., J.L., and Y.D.; Supervision, J.L., and Y.D.; Funding Acquisition,
558 J.L., and Y.D.

559

560

561

562

563

564

565

566

567

568

569 **REFERENCES**

570

- 571 1. Hsu, P.D., Lander, E.S. & Zhang, F. Development and applications of CRISPR-
572 Cas9 for genome engineering. *Cell* **157**, 1262-1278 (2014).
- 573 2. Joung, J.K. & Sander, J.D. TALENs: a widely applicable technology for targeted
574 genome editing. *Nat Rev Mol Cell Biol* **14**, 49-55 (2013).
- 575 3. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome
576 editing with engineered zinc finger nucleases. *Nat Rev Genet* **11**, 636-646 (2010).
- 577 4. Jasin, M. & Haber, J.E. The democratization of gene editing: Insights from site-
578 specific cleavage and double-strand break repair. *DNA Repair (Amst)* **44**, 6-16 (2016).
- 579 5. Tycko, J., Myer, V.E. & Hsu, P.D. Methods for Optimizing CRISPR-Cas9 Genome
580 Editing Specificity. *Mol Cell* **63**, 355-370 (2016).
- 581 6. Doench, J.G. et al. Optimized sgRNA design to maximize activity and minimize
582 off-target effects of CRISPR-Cas9. *Nat Biotechnol* **34**, 184-191 (2016).
- 583 7. Whyte, J.J. et al. Gene targeting with zinc finger nucleases to produce cloned eGFP
584 knockout pigs. *Mol Reprod Dev* **78**, 2 (2011).
- 585 8. Duda, K. et al. High-efficiency genome editing via 2A-coupled co-expression of
586 fluorescent proteins and zinc finger nucleases or CRISPR/Cas9 nickase pairs. *Nucleic
587 Acids Res* **42**, e84 (2014).
- 588 9. Certo, M.T. et al. Tracking genome engineering outcome at individual DNA
589 breakpoints. *Nat Methods* **8**, 671-676 (2011).
- 590 10. Kim, H. et al. Surrogate reporters for enrichment of cells with nuclease-induced
591 mutations. *Nat Methods* **8**, 941-943 (2011).
- 592 11. Aguirre, A.J. et al. Genomic Copy Number Dictates a Gene-Independent Cell
593 Response to CRISPR/Cas9 Targeting. *Cancer Discov* **6**, 914-929 (2016).
- 594 12. Chu, V.T. et al. Increasing the efficiency of homology-directed repair for CRISPR-
595 Cas9-induced precise gene editing in mammalian cells. *Nat Biotechnol* **33**, 543-548
596 (2015).
- 597 13. Doyon, Y. et al. Transient cold shock enhances zinc-finger nuclease-mediated gene
598 disruption. *Nat Methods* **7**, 459-460 (2010).
- 599 14. Gutschner, T., Haemmerle, M., Genovese, G., Draetta, G.F. & Chin, L. Post-
600 translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. *Cell
601 Rep* **14**, 1555-1566 (2016).

- 602 15. Lin, S., Staahl, B.T., Alla, R.K. & Doudna, J.A. Enhanced homology-directed
603 human genome engineering by controlled timing of CRISPR/Cas9 delivery. *Elife* **3**,
604 e04766 (2014).
- 605 16. Maruyama, T. et al. Increasing the efficiency of precise genome editing with
606 CRISPR-Cas9 by inhibition of nonhomologous end joining. *Nat Biotechnol* **33**, 538-542
607 (2015).
- 608 17. Pinder, J., Salsman, J. & Dellaire, G. Nuclear domain 'knock-in' screen for the
609 evaluation and identification of small molecule enhancers of CRISPR-based genome
610 editing. *Nucleic Acids Res* **43**, 9379-9392 (2015).
- 611 18. Arribere, J.A. et al. Efficient marker-free recovery of custom genetic modifications
612 with CRISPR/Cas9 in *Caenorhabditis elegans*. *Genetics* **198**, 837-846 (2014).
- 613 19. Kim, H. et al. A co-CRISPR strategy for efficient genome editing in *Caenorhabditis*
614 *elegans*. *Genetics* **197**, 1069-1080 (2014).
- 615 20. Moriarity, B.S. et al. Simple and efficient methods for enrichment and isolation of
616 endonuclease modified cells. *PLoS One* **9**, e96114 (2014).
- 617 21. Shy, B.R., MacDougall, M.S., Clarke, R. & Merrill, B.J. Co-incident insertion
618 enables high efficiency genome engineering in mouse embryonic stem cells. *Nucleic*
619 *Acids Res* (2016).
- 620 22. Laursen, M., Gregersen, J.L., Yatime, L., Nissen, P. & Fedosova, N.U. Structures
621 and characterization of digoxin- and bufalin-bound Na⁺,K⁺-ATPase compared with the
622 ouabain-bound complex. *Proc Natl Acad Sci U S A* **112**, 1755-1760 (2015).
- 623 23. Ogawa, H., Shinoda, T., Cornelius, F. & Toyoshima, C. Crystal structure of the
624 sodium-potassium pump (Na⁺,K⁺-ATPase) with bound potassium and ouabain. *Proc*
625 *Natl Acad Sci U S A* **106**, 13742-13747 (2009).
- 626 24. Croyle, M.L., Woo, A.L. & Lingrel, J.B. Extensive random mutagenesis analysis of
627 the Na⁺/K⁺-ATPase alpha subunit identifies known and previously unidentified amino
628 acid residues that alter ouabain sensitivity--implications for ouabain binding. *Eur J*
629 *Biochem* **248**, 488-495 (1997).
- 630 25. Price, E.M., Rice, D.A. & Lingrel, J.B. Structure-function studies of Na,K-ATPase.
631 Site-directed mutagenesis of the border residues from the H1-H2 extracellular domain of
632 the alpha subunit. *J Biol Chem* **265**, 6638-6641 (1990).
- 633 26. Brinkman, E.K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative
634 assessment of genome editing by sequence trace decomposition. *Nucleic Acids Res* **42**,
635 e168 (2014).
- 636 27. Zetsche, B. et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-
637 Cas system. *Cell* **163**, 759-771 (2015).

- 638 28. Slaymaker, I.M. et al. Rationally engineered Cas9 nucleases with improved
639 specificity. *Science* **351**, 84-88 (2016).
- 640 29. Wang, T., Wei, J.J., Sabatini, D.M. & Lander, E.S. Genetic screens in human cells
641 using the CRISPR-Cas9 system. *Science* **343**, 80-84 (2014).
- 642 30. Zetsche, B. et al. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA
643 array. *Nat Biotechnol* **35**, 31-34 (2017).
- 644 31. van Overbeek, M. et al. DNA Repair Profiling Reveals Nonrandom Outcomes at
645 Cas9-Mediated Breaks. *Mol Cell* **63**, 633-646 (2016).
- 646 32. Kim, D. et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in
647 human cells. *Nat Biotechnol* **34**, 863-868 (2016).
- 648 33. Kleinstiver, B.P. et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases
649 in human cells. *Nat Biotechnol* **34**, 869-874 (2016).
- 650 34. Dalvai, M. et al. A Scalable Genome-Editing-Based Approach for Mapping
651 Multiprotein Complexes in Human Cells. *Cell Rep* **13**, 621-633 (2015).
- 652 35. Jacquet, K. et al. The TIP60 Complex Regulates Bivalent Chromatin Recognition
653 by 53BP1 through Direct H4K20me Binding and H2AK15 Acetylation. *Mol Cell* **62**,
654 409-421 (2016).
- 655 36. Genovese, P. et al. Targeted genome editing in human repopulating haematopoietic
656 stem cells. *Nature* **510**, 235-240 (2014).
- 657 37. Dever, D.P. et al. CRISPR/Cas9 beta-globin gene targeting in human
658 haematopoietic stem cells. *Nature* (2016).
- 659 38. DeWitt, M.A. et al. Selection-free genome editing of the sickle mutation in human
660 adult hematopoietic stem/progenitor cells. *Sci Transl Med* **8**, 360ra134 (2016).
- 661 39. Hoban, M.D. et al. CRISPR/Cas9-Mediated Correction of the Sickle Mutation in
662 Human CD34+ cells. *Mol Ther* **24**, 1561-1569 (2016).
- 663 40. Fares, I. et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of
664 human hematopoietic stem cell self-renewal. *Science* **345**, 1509-1512 (2014).
- 665 41. Lingrel, J.B. The physiological significance of the cardiotonic steroid/ouabain-
666 binding site of the Na,K-ATPase. *Annu Rev Physiol* **72**, 395-412 (2010).
- 667 42. Nagree, M.S., Lopez-Vasquez, L. & Medin, J.A. Towards in vivo amplification:
668 Overcoming hurdles in the use of hematopoietic stem cells in transplantation and gene
669 therapy. *World J Stem Cells* **7**, 1233-1250 (2015).

670 43. Mali, P. et al. RNA-guided human genome engineering via Cas9. *Science* **339**, 823-
671 826 (2013).

672 44. Guschin, D.Y. et al. A rapid and general assay for monitoring endogenous gene
673 modification. *Methods Mol Biol* **649**, 247-256 (2010).

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692


693

694


695

a


ATP1A1 SpCas9 targets



b




c




d

ssODN Q118R N129D (RD)



ssODN Q118D N129R (DR)



e




Figure 1

696 **Figure 1** | CRISPR-Cas9-driven editing of *ATPIAI* via NHEJ and HDR induces cellular
697 resistance to ouabain. **(a)** Schematic representation of SpCas9 target sites surrounding
698 DNA encoding the first extracellular loop of human *ATPIAI*. Annotated are the positions
699 of residues Q118 and N129, exon/intron boundary, protospacer adjacent motifs (PAM)
700 and four potential SpCas9 target sequences (Targets 1-4). **(b)** The indicated pUC19-based
701 sgRNA expression vectors (G1-G4) (500 ng) were transfected into K562 cells stably
702 expressing wild-type SpCas9 from the *AAVSI* safe harbor locus. Genomic DNA was
703 harvested 10 days post-transfection and the Surveyor assay was used to determine the
704 frequency of SpCas9-induced insertions and deletions, indicated as the % Indels at the
705 base of each lane. Where indicated cells were treated with 0.5 μ M ouabain for 7 days
706 starting 3 days post transfection. An expression vector encoding EGFP (-) was used as a
707 negative control. **(c)** Genomic DNA from **(b)** was amplified by PCR, TOPO cloned and
708 sequenced. **(d)** Schematic representation of the intronic SpCas9 target site G3 and partial
709 sequences of single-stranded oligodeoxynucleotides (ssODNs) donors used to introduce
710 the Q118D/R and N129D/R mutations. Annotated are novel restriction sites introduced to
711 monitor the insertion of ssODN-specified mutations. **(e)** The pUC19-based G3 sgRNA
712 expression vector (500 ng) was co-transfected into K562 cells stably expressing wild-type
713 SpCas9 along with the indicated ssODNs (10 pmole). Cells were treated as in **(b)** and a
714 ClaI RFLP assay was used to determine the frequency of SpCas9-induced HDR at the
715 cleavage site indicated as the % HDR at the base of each lane. An expression vector
716 encoding EGFP (-) was used as a negative control.

717

718




Figure 2

719 **Figure 2** | Enrichment of cells with CRISPR-driven targeted mutagenesis by co-editing
720 the *ATP1A1* gene via NHEJ. **(a)** Experimental strategy for the co-enrichment of NHEJ-
721 driven mutations at a second locus. **(b)** Schematic of the dual eSpCas9(1.1) and tandem
722 U6-driven sgRNAs expression vector. **(c)** K562 cells were transfected with 50ng and
723 500ng of a vector expressing eSpCas9(1.1) and tandem U6-driven sgRNAs targeting
724 *ATP1A1* and *EMX1*. Cells were treated or not with 0.5 μ M ouabain for 7-10 days starting
725 3 days post-transfection. Genomic DNA was harvested and the TIDE assay was used to
726 determine the frequency of indels. **(d)** Same as in **(c)** but co-targeting *AAVS1*. **(e)**
727 Schematic of the dual AsCpf1 and U6-driven crRNA array expression vector. **(f)** K562
728 cells were transfected with 500ng of the vectors shown in **(e)**, treated and assayed for
729 indels as **(c)**. **(g)** Same as in **(e)**. **(h)** Same as in **(f)** but using 1 μ g of the vector.

730

731

732

733

734

735

736

737

738

739

740

741




Figure 3

742 **Figure 3** | Enrichment of cells with targeted integrations at endogenous loci by co-editing
743 the *ATP1A1* gene via HDR. **(a)** Targeting scheme for the integration of mAG1 to the C-
744 terminus of H2BK. **(b)** K562 cells were transfected with a vector expressing
745 eSpCas9(1.1) and tandem U6-driven sgRNAs targeting *ATP1A1* and *HIST1H2BK* along
746 with *ATP1A1* ssODN RD and a plasmid donor containing a mAG1 cassette. In addition,
747 cells were transfected with a wild-type SpCas9 expression vector and two pUC19-based
748 sgRNA vectors. Cells were treated or not with 0.5 μ M ouabain for 10 days starting 3 days
749 post-transfection and flow cytometry was used to determine the % of mAG1 positive
750 cells in each population. **(c)** Fluorescence imaging of ouabain treated cells expressing the
751 H2BK-mAG1 fusion. **(d)** Targeting scheme for the integration of Clover and mRuby2 to
752 the N-terminus of lamin. **(e)** K562 cells were transfected with a pX330-based vector (WT
753 SpCas9) expressing the *LMNA* sgRNA, a pUC19-based *ATP1A1* sgRNA vector, along
754 with *ATP1A1* ssODN RD and a plasmid donor containing a Clover or an mRuby2
755 cassette. Cells were treated as **(b)** and flow cytometry was used to determine the % of
756 Clover and mRuby2 positive cells in each population. **(f)** A *Cla*I RFLP assay was used to
757 determine the frequency of SpCas9-induced HDR at the *ATP1A1* locus indicated as the %
758 HDR at the base of each lane. Transfection conditions can be found in Supplementary
759 Table 1.
760
761
762
763
764




Figure 4

765 **Figure 4** | Endogenous tagging and tandem affinity purification of the native NuA4/TIP60
766 complex from co-selected cell pools. **(a)** Schematic representation of the experiment. **(b)** Gene
767 tagging scheme. **(c)** K562 cells were transfected with a vector expressing eSpCas9(1.1) and a
768 sgRNA targeting *ATPIA1* along with a pUC19-based sgRNA vector for *EPC1* or *EP400* and
769 *ATPIA1* ssODN RD and a plasmid donor containing a 3xFLAG-2xStrep epitope sequence.
770 Cells were treated or not with 0.5 μ M ouabain for 10 days starting 3 days post-transfection and
771 a PCR-based assay (out-out PCR) was used to detect targeted integration (TI) of the tag
772 sequence at the C-terminus of EPC1 and EP400. Primers are located outside of the homology
773 arms and are designed to yield a longer PCR product if the tag is inserted. **(d)** Western blot
774 analysis on whole cell extracts to detect the expression of EPC1-tag and EP400-tag proteins.
775 The FLAG M2 antibody was used to detect tagged proteins and the tubulin antibody was used
776 as a loading control. **(e)** Silver stained SDS-PAGE showing the purified EPC1 and EP400
777 complexes.

778

779

780

781

782

783

784

785

786

a

E6

ACAGACACCATGGTGCATCTGACTCCTGAGGAGAAGTCTGCCGTTACTGCCCTGTGGGGCAAGGTGAACGTG
 5' UTR M V H L T P E E K S A V T A L W G K V N V **HBB**
 TGCTCTGTGGTACCACGTAGACTGAGGACTCCTCTTCAGACGGCAATGACGGGACACCCCGTTCCACTTGCAC
PAM SpCas9 Target


E6V PstI

ACAGACACCATGGTGCATCTGACTCCTGTGGAGAAGTCTGCAGTTACTGCCCTGTGGGGCAAGGTGAACGTG
 5' UTR M V H L T P V E K S A V T A L W G K V N V **HDR #1**
 TGCTCTGTGGTACCACGTAGACTGAGGACACCTCTTCAGACGTC AATGACGGGACACCCCGTTCCACTTGCAC
Mutated PAM SpCas9 Target

E6V PstI

ACAGACACCATGGTGCATCTGACTCCTGTCGAGAAGTCTGCAGTTACTGCCCTGTGGGGCAAGGTGAACGTG
 5' UTR M V H L T P V E K S A V T A L W G K V N V **HDR #2**
 TGCTCTGTGGTACCACGTAGACTGAGGACAGCTCTTCAGACGTC AATGACGGGACACCCCGTTCCACTTGCAC
PshAI Mutated PAM SpCas9 Target

b



c





Figure 5

787 **Figure 5** | Enrichment of HDR-driven events in primary human cord blood (CB) CD34⁺
788 cells upon selection with ouabain. **(a)** Schematic representation of SpCas9 target site in
789 *HBB* and predicted HDR outcomes dictated by two different ssODNs donors used to
790 introduce the E6V mutation. Annotated are the positions of E6 residue, 5' UTR,
791 protospacer adjacent motifs (PAM) and novel restriction sites introduced to monitor the
792 insertion of ssODN-specified mutations. HDR#2 bears an additional PshAI site to
793 directly monitor conversion of the E6V mutation. **(b)** Cultured CD34⁺ cells were
794 electroporated with *ATP1A1* and *HBB* RNPs along with *ATP1A1* ssODN RD and *HBB*
795 ssODN#1 and grown in the presence of 0.5µM ouabain starting 5 days post-transfection.
796 Genomic DNA was harvested at 13 days post-transfection and a PstI RFLP assay was
797 used to determine the frequency of SpCas9-induced HDR, which is indicated as the %
798 HDR at the base of each lane. Recombinant Cas9 was used as a negative control (-). **(c)**
799 CD34⁺ cells were treated as in **(b)** but using *HBB* ssODN#2 and assayed by RFLP for
800 both PstI and PshAI sites.

801

802

803

804

805